Combination Doxorubicin and Interferon-α Therapy Stimulates Immunogenicity of Murine Pancreatic Cancer Panc02 Cells via Up-regulation of NKG2D ligands and MHC Class I |
Wang, Wen-Jia
(Institute of Pharmacy, Tumor Hospital of Jilin Province)
Qin, Si-Hao (Institute of Medicine, Tumor Hospital of Jilin Province) Zhang, Ji-Wei (Department of Neurosurgery, Tumor Hospital of Jilin Province) Jiang, Yue-Yao (Institute of Pharmacy, Tumor Hospital of Jilin Province) Zhang, Jin-Nan (Department of Neurosurgery, China-Japan Friendship Hospital) Zhao, Lei (Institute of Frontier Medical Science, Jilin University) |
1 | Bandyopadhyay A, Wang L, Agyin J, et al (2010). Doxorubicin in combination with a small TGF- inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One, 5, 10365. DOI |
2 | Casares N, Pequignot MO, Tesniere A, et al (2005). Caspasedependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med, 202, 1691-701. DOI ScienceOn |
3 | Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM (2002). Cutting edge: murine UL16-binding proteinlike transcript 1: a newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol, 169, 4079-83. DOI |
4 | Gabrilovich DI (2007). Combination of chemotherapy and immunotherapy for cancer: a paradigm revisited. Lancet Oncol, 8, 2-3. DOI |
5 | Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH (2000). Ligands for the murine NKG2D receptor expression by tumor cells and activation of NK cells and macrophages. Nat Immunol, 1, 119-26. DOI ScienceOn |
6 | Gasser S, Orsulic S, Brown EJ, Raulet DH (2005). The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 436, 1186-90. DOI ScienceOn |
7 | Gromme M, Neefjes J (2002). Antigen degradation or presentation by MHC class I molecules via classical and non-classical pathways. Mol Immunol, 39, 181-202. DOI ScienceOn |
8 | Gutterman JU (1994). Cytokine therapeutics lessons from interferon alpha. P Natl Acad Sci USA, 91, 1198-205. DOI ScienceOn |
9 | Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. Ca-Cancer J Clin, 60, 277-300. DOI |
10 | Karre K (2002). NK cells, MHC class I molecules and the missing self. Scand J Immunol, 55, 221-8. DOI ScienceOn |
11 | Ke M, Wang H, Zhang M, et al (2014). The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. Biochem Pharmacol, 89, 119-30. DOI |
12 | Marrack P, Kappler J, Mitchell T (1999). Type I interferons keep activated T cells alive. J Exp Med, 189, 521-30. DOI |
13 | Khallouf H, Marten A, Serba S, et al (2012). 5-Fluorouracil and interferon- immunochemotheraoy enhances immunogenicity of murine pancreatic cancer through upregulation of NKG2D ligangs and MHC class I. J Immunother, 35, 245-53. DOI |
14 | Ma JH, Patrut E, Schmidt J, et al (2005). Synergistic effects of interferon-alpha in combination with chemoradiation on human pancreatic adenocarcinoma. World J Gastroenterol, 11, 1521-8. DOI |
15 | Ma XL, Li YY, Zhang J, et al (2014). Prognostic role of circulating tumor cells in patients with pancreatic cancer: a meta-analysis. Asian Pac J Cancer Prev, 15, 6015-20. 과학기술학회마을 DOI |
16 | Mattarollo SR, Loi S, Duret H, et al (2011). Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res, 71, 4809-20. DOI |
17 | Neoptolemos JP, Stocken DD, Friess H, et al (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New Engl J Med, 350, 1200-10. DOI ScienceOn |
18 | Nugroho AE, Hermawan A, Nastiti K, Suven Elisa P, et al (2012). Immunomodulatory effects of hexane insoluble fraction of Ficus septica Burm. F. in doxorubicin-treated rats. Asian Pac J Cancer Prev, 13, 5785-90. 과학기술학회마을 DOI ScienceOn |
19 | Pfeffer LM, Dinarello CA, Herberman RB, et al (1998). Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res, 58, 2489-99. |
20 | Pende D, Rivera P, Marcenaro S, et al (2002). Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes:analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res, 62, 6178-86. |
21 | Raulet DH (2003). Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol, 3, 781-90. DOI ScienceOn |
22 | Salih HR, Antropius H, Gieseke F, et al (2003). Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood, 102, 1389-96. DOI |
23 | Sandel MH, Speetjens FM, Menon AG, et al (2005). Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol Immunol, 42, 541-6. DOI ScienceOn |
24 | Savage P, Costelna D, Moore J, Gore ME (1997). A phase II study of continuous infusional 5-Fluorouracil and subcutaneous Interleukin-2 (IL-2) in metastatic renal cancer. Eur J Cancer, 33, 1149-51. DOI ScienceOn |
25 | Sener SF, Fremgen A, Menck HR, Winchester DP (1999). Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surgeons, 18, 1-7. |
26 | Siddle, HV, Kreiss, A, Tovar C, et al (2013). Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrates immune escape by a contagious cancer. P Natl Acad Sca USA, 110, 5103-8. DOI ScienceOn |
27 | Uram JN, Le DT (2013). Current advances in immunotherapy for pancreatic cancer. Curr Prob Cancer, 37, 273-9. DOI |
28 | Soriani A, Zingoni A, Cerboni C, et al (2009). ATM-ATRdependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood, 113, 3503-11. DOI |
29 | Stojanovic A, Cerwenka A (2011). Natural killer cells and solid tumors. J Innate Immun, 3, 355-64. DOI |
30 | Tacar O, Sriamornsak P, Dass CR (2013). Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmaco, 65, 157-70. DOI |
31 | Zhao L, Wang WJ, Zhang JN, Zhang XY (2014). 5-Fluorouracil and interleukin-2 immunochemotherapy enhances immunogenicity of non-small cell lung cancer A549 cells through upregulation of NKG2D ligands. Asian Pac J Cancer Prev, 15, 4039-44. DOI ScienceOn |